HER2+ BC patients were treated with doxorubicin/cyclophosphamide/taxol together with anti-HER2 targeted therapy, including 24 patients (39%) with residual tumors and the other 36 patients (61%) with pCR. The gene discussed is ERBB2; the disease is breast cancer.